KRAS and colorectal cancer: For example, based on clinical trials and various studies examining the efficacy of anti-epidermal growth factor receptor (EGFR) therapies such as cetuximab and panitumumab in treating colorectal cancer patients [56–61], the FDA revised their recommendation to exclude patients with KRAS G12 or G13 mutations from such treatment [62].